DENGUE VIRUS MRNA VACCINE AND METHOD AGAINST DENGUE VIRUS INFECTION USING THE SAME

The present invention relates to a dengue virus messenger ribonucleic acid (mRNA) vaccine. In particular, the vaccine includes an mRNA encoding a mutant envelop (E) protein of dengue virus at position 8 and/or 101 formulated in lipid nanoparticles. The mRNA vaccine of the present invention is safe a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	WU, Han-Chung, LIN, Hsiu-Ting, SU, Shih-Chieh
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to a dengue virus messenger ribonucleic acid (mRNA) vaccine. In particular, the vaccine includes an mRNA encoding a mutant envelop (E) protein of dengue virus at position 8 and/or 101 formulated in lipid nanoparticles. The mRNA vaccine of the present invention is safe and effective, which causes enhanced production of neutralizing antibodies against multiple serotypes of dengue virus and reduced antibody dependent enhancement (ADE) response. La présente invention concerne un vaccin à acide ribonucléique messager (ARNm) contre le virus de la dengue. En particulier, le vaccin comprend un ARNm codant pour une protéine d'enveloppe mutante (E) du virus de la dengue en position 8 et/ou 101 formulée dans des nanoparticules lipidiques. Le vaccin à ARNm de la présente invention est sûr et efficace, et mène à une meilleure production d'anticorps neutralisants ciblant de multiples sérotypes du virus de la dengue et à une réduction de la réponse d'aggravation dépendante des anticorps (ADE).